3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
53
Lymphoma, Mantle-Cell
31
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Non-Hodgkin
14
Lymphoma
11
Leukemia, B-Cell
6
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Leukemia
5
Waldenstrom Macroglobulinemia
4
Multiple Myeloma
3
Recurrence
2
Pancreatic Neoplasms
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Pyloric Stenosis, Hypertrophic
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neuritis
1
Neoplasms
1
Neoplasm, Residual
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Diseases
1
Interventions
Peripheral Blood Stem Cell Transplantation
26
Rituximab
20
Cyclophosphamide
18
fludarabine phosphate
17
Mycophenolic Acid
16
Tacrolimus
14
Cyclosporine
14
Whole-Body Irradiation
12
Filgrastim
11
Etoposide
10
Radiotherapy
8
Methotrexate
8
Busulfan
8
Therapeutics
7
Methylprednisolone
7
Antilymphocyte Serum
7
Cladribine
6
Lenalidomide
5
Flow Cytometry
5
obinutuzumab
4
immunotoxin HA22
4
Vorinostat
4
Vemurafenib
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Ondansetron
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
Dexamethasone
4
Cord Blood Stem Cell Transplantation
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Leukemia, Hairy Cell
×
acalabrutinib
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts